LON:NFX Nuformix (NFX) Share Price, News & Analysis GBX 0.10 0.00 (0.00%) As of 10:35 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsBuy This Stock About Nuformix Stock (LON:NFX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nuformix alerts:Sign Up Key Stats Today's Range 0.10▼ 0.1250-Day Range 0.06▼ 0.1852-Week Range 0.04▼ 0.30Volume27.50 million shsAverage Volume51.65 million shsMarket Capitalization£1.29 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 293Consensus RatingBuy Company OverviewNuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.Read More… Remove Ads Nuformix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreNFX MarketRank™: Nuformix scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNuformix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuformix has only been the subject of 1 research reports in the past 90 days.Read more about Nuformix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuformix is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuformix is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuformix has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NFX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuformix does not currently pay a dividend.Dividend GrowthNuformix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NFX. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Nuformix to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nuformix insiders have not sold or bought any company stock.Percentage Held by Insiders12.44% of the stock of Nuformix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.12% of the stock of Nuformix is held by institutions.Read more about Nuformix's insider trading history. Receive NFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuformix and its competitors with MarketBeat's FREE daily newsletter. Email Address NFX Stock News HeadlinesNuformix Advances NXP002 in Fibrosis Treatment EffortsJanuary 29, 2025 | tipranks.comNuformix plc (NFX.L) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. April 3, 2025 | Paradigm Press (Ad)Nuformix Share Chat (NFX)September 17, 2024 | lse.co.ukNuformix plc (NFX.L)September 15, 2024 | ca.finance.yahoo.comNuformix PLC NFXNovember 16, 2023 | morningstar.comNuformix gets patent in Japan for pulmonary fibrosis treatment NXP002October 23, 2023 | lse.co.ukNuformix to fund its unlicensed programs with NXP001 windfallOctober 5, 2023 | finance.yahoo.comSee More Headlines NFX Stock Analysis - Frequently Asked Questions How have NFX shares performed this year? Nuformix's stock was trading at GBX 0.05 at the beginning of 2025. Since then, NFX stock has increased by 133.3% and is now trading at GBX 0.11. View the best growth stocks for 2025 here. How were Nuformix's earnings last quarter? Nuformix plc (LON:NFX) posted its earnings results on Wednesday, January, 29th. The company reported ($0.46) EPS for the quarter. How do I buy shares of Nuformix? Shares of NFX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Nuformix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuformix investors own include Allena Pharmaceuticals (ALNA), Rolls-Royce Holdings plc (RR), UK Oil & Gas (UKOG), 88 Energy (88E), Ampliphi Biosciences (APHB), Argo Blockchain (ARB) and Ardelyx (ARDX). Company Calendar Last Earnings1/29/2025Today4/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:NFX Previous SymbolLON:LVRT CIKN/A Webwww.levrett.com Phone44 1223 423 667FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 293 High Stock Price TargetGBX 293 Low Stock Price TargetGBX 293 Potential Upside/Downside+278,947.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-383,402.73 Net MarginsN/A Pretax MarginN/A Return on Equity-5.68% Return on Assets-17.20% Debt Debt-to-Equity RatioN/A Current Ratio1.12 Quick Ratio3.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.03 per share Price / Cash Flow3.55 Book ValueGBX 0.54 per share Price / Book0.19Miscellaneous Outstanding Shares1,231,809,091Free FloatN/AMarket Cap£1.29 million OptionableNot Optionable Beta1.22 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (LON:NFX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuformix plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuformix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.